Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
45
XBIO Quote, Financials, Valuation and Earnings
Last price:
$2.30
Seasonality move
:
-10.95%
Day range:
$2.35 - $2.55
52-week range:
$1.90 - $13.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.38x
P/B ratio:
1.48x
Volume:
8.4K
Avg. volume:
26.3K
1-year change:
-34.95%
Market cap:
$5.8M
Revenue:
$2.5M
EPS (TTM):
-$2.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XBIO
Xenetic Biosciences, Inc.
|
$692.6K | -- | 6.75% | -- | -- |
|
BSEM
BioStem Technologies, Inc.
|
$55.2M | $0.02 | -37.86% | -100% | $25.5000 |
|
GBLX
GB Sciences, Inc.
|
-- | -- | -- | -- | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$81M | -$0.18 | 58.55% | -61.17% | $8.80 |
|
PKTX
Protokinetix, Inc.
|
-- | -- | -- | -- | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XBIO
Xenetic Biosciences, Inc.
|
$2.55 | -- | $5.8M | -- | $0.00 | 0% | 1.38x |
|
BSEM
BioStem Technologies, Inc.
|
$5.5500 | $25.5000 | $93M | 6.52x | $0.00 | 0% | 0.52x |
|
GBLX
GB Sciences, Inc.
|
$0.0003 | -- | $122.1K | -- | $0.00 | 0% | 1.26x |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$3.79 | $8.80 | $1.5B | -- | $0.00 | 0% | 5.14x |
|
PKTX
Protokinetix, Inc.
|
$0.0067 | -- | $2.6M | 23.85x | $0.00 | 0% | -- |
|
PSTV
Plus Therapeutics, Inc.
|
$0.30 | $5.50 | $41.2M | -- | $0.00 | 0% | 4.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XBIO
Xenetic Biosciences, Inc.
|
-- | 3.589 | -- | 3.71x |
|
BSEM
BioStem Technologies, Inc.
|
6.34% | -0.168 | 4.31% | 3.87x |
|
GBLX
GB Sciences, Inc.
|
-- | 5.767 | -- | -- |
|
IOVA
Iovance Biotherapeutics, Inc.
|
6.61% | -2.426 | 4.56% | 2.74x |
|
PKTX
Protokinetix, Inc.
|
-- | 1.031 | -- | 0.00x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -3.087 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XBIO
Xenetic Biosciences, Inc.
|
-- | -$544.7K | -59.39% | -59.39% | -53.04% | -$658.2K |
|
BSEM
BioStem Technologies, Inc.
|
$9.2M | $1.4M | 44.01% | 48.25% | 13.83% | -- |
|
GBLX
GB Sciences, Inc.
|
-- | -$157.8K | -- | -- | -- | -$107.7K |
|
IOVA
Iovance Biotherapeutics, Inc.
|
$34.1M | -$73.5M | -50.85% | -54.64% | -84.79% | -$61.9M |
|
PKTX
Protokinetix, Inc.
|
-$12.6K | -$84.9K | -111.59% | -111.59% | -- | -$9.5K |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Xenetic Biosciences, Inc. vs. Competitors
-
Which has Higher Returns XBIO or BSEM?
BioStem Technologies, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of 7.27%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat BioStem Technologies, Inc.'s return on equity of 48.25%.
Company Gross Margin Earnings Per Share Invested Capital XBIOXenetic Biosciences, Inc.-- -$0.33 $4M BSEMBioStem Technologies, Inc.87.95% $0.03 $53.4M -
What do Analysts Say About XBIO or BSEM?
Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1468.63%. On the other hand BioStem Technologies, Inc. has an analysts' consensus of $25.5000 which suggests that it could grow by 359.46%. Given that Xenetic Biosciences, Inc. has higher upside potential than BioStem Technologies, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than BioStem Technologies, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBIOXenetic Biosciences, Inc.0 1 0 BSEMBioStem Technologies, Inc.0 0 0 -
Is XBIO or BSEM More Risky?
Xenetic Biosciences, Inc. has a beta of 2.259, which suggesting that the stock is 125.93% more volatile than S&P 500. In comparison BioStem Technologies, Inc. has a beta of -0.050, suggesting its less volatile than the S&P 500 by 104.97%.
-
Which is a Better Dividend Stock XBIO or BSEM?
Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioStem Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. BioStem Technologies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIO or BSEM?
Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than BioStem Technologies, Inc. quarterly revenues of $10.5M. Xenetic Biosciences, Inc.'s net income of -$509.9K is lower than BioStem Technologies, Inc.'s net income of $761.1K. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while BioStem Technologies, Inc.'s PE ratio is 6.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.38x versus 0.52x for BioStem Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIOXenetic Biosciences, Inc.1.38x -- $1M -$509.9K BSEMBioStem Technologies, Inc.0.52x 6.52x $10.5M $761.1K
-
Which has Higher Returns XBIO or GBLX?
GB Sciences, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of --. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat GB Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIOXenetic Biosciences, Inc.-- -$0.33 $4M GBLXGB Sciences, Inc.-- -$0.00 -- -
What do Analysts Say About XBIO or GBLX?
Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1468.63%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Xenetic Biosciences, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than GB Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBIOXenetic Biosciences, Inc.0 1 0 GBLXGB Sciences, Inc.0 0 0 -
Is XBIO or GBLX More Risky?
Xenetic Biosciences, Inc. has a beta of 2.259, which suggesting that the stock is 125.93% more volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.460, suggesting its more volatile than the S&P 500 by 1045.961%.
-
Which is a Better Dividend Stock XBIO or GBLX?
Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIO or GBLX?
Xenetic Biosciences, Inc. quarterly revenues are $1M, which are larger than GB Sciences, Inc. quarterly revenues of --. Xenetic Biosciences, Inc.'s net income of -$509.9K is lower than GB Sciences, Inc.'s net income of -$190.5K. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.38x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIOXenetic Biosciences, Inc.1.38x -- $1M -$509.9K GBLXGB Sciences, Inc.1.26x -- -- -$190.5K
-
Which has Higher Returns XBIO or IOVA?
Iovance Biotherapeutics, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of -82.92%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.64%.
Company Gross Margin Earnings Per Share Invested Capital XBIOXenetic Biosciences, Inc.-- -$0.33 $4M IOVAIovance Biotherapeutics, Inc.39.31% -$0.18 $748M -
What do Analysts Say About XBIO or IOVA?
Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1468.63%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $8.80 which suggests that it could grow by 132.19%. Given that Xenetic Biosciences, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Iovance Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBIOXenetic Biosciences, Inc.0 1 0 IOVAIovance Biotherapeutics, Inc.6 3 0 -
Is XBIO or IOVA More Risky?
Xenetic Biosciences, Inc. has a beta of 2.259, which suggesting that the stock is 125.93% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.690, suggesting its less volatile than the S&P 500 by 30.977%.
-
Which is a Better Dividend Stock XBIO or IOVA?
Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIO or IOVA?
Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $86.7M. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than Iovance Biotherapeutics, Inc.'s net income of -$71.9M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.38x versus 5.14x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIOXenetic Biosciences, Inc.1.38x -- $1M -$509.9K IOVAIovance Biotherapeutics, Inc.5.14x -- $86.7M -$71.9M
-
Which has Higher Returns XBIO or PKTX?
Protokinetix, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of --. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Protokinetix, Inc.'s return on equity of -111.59%.
Company Gross Margin Earnings Per Share Invested Capital XBIOXenetic Biosciences, Inc.-- -$0.33 $4M PKTXProtokinetix, Inc.-- -$0.00 $250.4K -
What do Analysts Say About XBIO or PKTX?
Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1468.63%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Xenetic Biosciences, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Protokinetix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBIOXenetic Biosciences, Inc.0 1 0 PKTXProtokinetix, Inc.0 0 0 -
Is XBIO or PKTX More Risky?
Xenetic Biosciences, Inc. has a beta of 2.259, which suggesting that the stock is 125.93% more volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.654, suggesting its less volatile than the S&P 500 by 34.642%.
-
Which is a Better Dividend Stock XBIO or PKTX?
Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIO or PKTX?
Xenetic Biosciences, Inc. quarterly revenues are $1M, which are larger than Protokinetix, Inc. quarterly revenues of --. Xenetic Biosciences, Inc.'s net income of -$509.9K is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.38x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIOXenetic Biosciences, Inc.1.38x -- $1M -$509.9K PKTXProtokinetix, Inc.-- 23.85x -- -$84.9K
-
Which has Higher Returns XBIO or PSTV?
Plus Therapeutics, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of -316.61%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XBIOXenetic Biosciences, Inc.-- -$0.33 $4M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About XBIO or PSTV?
Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1468.63%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1735.78%. Given that Plus Therapeutics, Inc. has higher upside potential than Xenetic Biosciences, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Xenetic Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBIOXenetic Biosciences, Inc.0 1 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is XBIO or PSTV More Risky?
Xenetic Biosciences, Inc. has a beta of 2.259, which suggesting that the stock is 125.93% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.
-
Which is a Better Dividend Stock XBIO or PSTV?
Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIO or PSTV?
Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.38x versus 4.80x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBIOXenetic Biosciences, Inc.1.38x -- $1M -$509.9K PSTVPlus Therapeutics, Inc.4.80x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
